ClariTrial | Search Clinical Trials

Explore/eye disease ophthalmology retina

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

153 results for “eye disease ophthalmology retina” · Recruiting

Page 1 of 11

Recruiting

Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

Phase 3Optic NeuritisMyelitisMyelitis, Transverse

High-dose corticosteroids (HDCS)High-dose corticosteroids (HDCS) and PLEX

Mayo Clinic382 participants24 sites · United StatesCompletes Apr 2029

Compare CT.gov Full analysis →

Recruiting

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Phase 1Phase 2Age-Related Macular DegenerationGeographic AtrophyNon-neovascular AMD

VOY-101

Perceive Biotherapeutics, Inc.60 participants11 sites · United States, Australia, IsraelCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Adaptive Optics Retinal Imaging

N/AGlaucoma, Primary Open Angle

oxygen inhalationAdaptive optics imaging

Food and Drug Administration (FDA)80 participants1 site · United StatesCompletes Sep 2026

Compare CT.gov Full analysis →

Recruiting

OCT in Rare Chorioretinal Diseases

N/ARetinal Artery OcclusionsPolypoidal Choroidal VasculopathyRetinal Arterial Macroaneurysm

Oregon Health and Science University150 participants1 site · United StatesCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Duration of Face Down Positioning for Full-Thickness Macular Hole Repair

N/AMacular Holes

3 Days of face-down positioning7 Days of face-down positioning

St. Joseph's Healthcare Hamilton40 participants1 site · CanadaCompletes May 2025

Compare CT.gov Full analysis →

Recruiting

Morphological Characteristics of the Maxillomandibular Region in a 3D Representation and the Refractive Status of the Eye

N/ARefractive Errors

No intervention; Observational study

University of Zagreb120 participants1 site · CroatiaCompletes Jun 2026

Compare CT.gov Full analysis →

Recruiting

Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery

Phase 3Retinal Detachment

UrsolvanPlacebo

Hopital Foch120 participants2 sites · FranceCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

Clinical and Genetic Analysis of ROP

N/ARetinopathy of Prematurity

No intervention administered.

Oregon Health and Science University2,000 participants5 sites · United StatesCompletes May 2024

Compare CT.gov Full analysis →

Recruiting

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Phase 3Age-related Macular Degeneration (AMD)Geographic Atrophy (GA)

PozelimabCemdisiranPlacebo

Regeneron Pharmaceuticals975 participants216 sites · United States, Austria, CanadaCompletes Nov 2027

Compare CT.gov Full analysis →

Recruiting

Vitreopapillary Interface and Optic Disc Morphology

N/APosterior Vitreous DetachmentVitreomacular TractionGlaucoma

OCT imaging/HRT imaging

Universitaire Ziekenhuizen KU Leuven350 participants1 site · BelgiumCompletes Apr 2025

Compare CT.gov Full analysis →

Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Phase 1Geographic AtrophyAge-related Macular Degeneration

RO7669330Syfovre™Izervay™

Hoffmann-La Roche132 participants16 sites · United StatesCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

N/AGeographic AtrophyMacular Degeneration

Avacincaptad pegol (ACP)

Astellas Pharma Global Development, Inc.1,000 participants65 sites · United StatesCompletes Jan 2030

Compare CT.gov Full analysis →

Recruiting

Pharmacokinetics and Safety of Dexamethasone Eye Drops in Preterm Infants

Phase 1Retinopathy of Prematurity

Dexamethasone Ophthalmic

Region Skane15 participants2 sites · SwedenCompletes Jun 2025

Compare CT.gov Full analysis →

Recruiting

REtinal Detachment Outcomes Study

N/ARetinal Detachment

Pars plana vitrectomyPars plana vitrectomy with scleral buckleSulfur hexafluoride gas tamponade+1 more

CHU de Quebec-Universite Laval560 participants1 site · CanadaCompletes Jul 2027

Compare CT.gov Full analysis →

Recruiting

Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant

N/ADiabetic Macular EdemaVisual ImpairmentDiabetes Mellitus

Anti-VEGF treatmentDexamethasone implantTreatment with intravitreal anti-VEGF OR Dexamethasone implant

Vastra Gotaland Region150 participants2 sites · SwedenCompletes Dec 2028

Compare CT.gov Full analysis →

1–15 of 153

Explore/eye disease ophthalmology retina

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

153 results for “eye disease ophthalmology retina” · Recruiting

Page 1 of 11

Recruiting

Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

Phase 3Optic NeuritisMyelitisMyelitis, Transverse

High-dose corticosteroids (HDCS)High-dose corticosteroids (HDCS) and PLEX

Mayo Clinic382 participants24 sites · United StatesCompletes Apr 2029

Compare CT.gov Full analysis →

Recruiting

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Phase 1Phase 2Age-Related Macular DegenerationGeographic AtrophyNon-neovascular AMD

VOY-101

Perceive Biotherapeutics, Inc.60 participants11 sites · United States, Australia, IsraelCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Adaptive Optics Retinal Imaging

N/AGlaucoma, Primary Open Angle

oxygen inhalationAdaptive optics imaging

Food and Drug Administration (FDA)80 participants1 site · United StatesCompletes Sep 2026

Compare CT.gov Full analysis →

Recruiting

OCT in Rare Chorioretinal Diseases

N/ARetinal Artery OcclusionsPolypoidal Choroidal VasculopathyRetinal Arterial Macroaneurysm

Oregon Health and Science University150 participants1 site · United StatesCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Duration of Face Down Positioning for Full-Thickness Macular Hole Repair

N/AMacular Holes

3 Days of face-down positioning7 Days of face-down positioning

St. Joseph's Healthcare Hamilton40 participants1 site · CanadaCompletes May 2025

Compare CT.gov Full analysis →

Recruiting

Morphological Characteristics of the Maxillomandibular Region in a 3D Representation and the Refractive Status of the Eye

N/ARefractive Errors

No intervention; Observational study

University of Zagreb120 participants1 site · CroatiaCompletes Jun 2026

Compare CT.gov Full analysis →

Recruiting

Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery

Phase 3Retinal Detachment

UrsolvanPlacebo

Hopital Foch120 participants2 sites · FranceCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

Clinical and Genetic Analysis of ROP

N/ARetinopathy of Prematurity

No intervention administered.

Oregon Health and Science University2,000 participants5 sites · United StatesCompletes May 2024

Compare CT.gov Full analysis →

Recruiting

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Phase 3Age-related Macular Degeneration (AMD)Geographic Atrophy (GA)

PozelimabCemdisiranPlacebo

Regeneron Pharmaceuticals975 participants216 sites · United States, Austria, CanadaCompletes Nov 2027

Compare CT.gov Full analysis →

Recruiting

Vitreopapillary Interface and Optic Disc Morphology

N/APosterior Vitreous DetachmentVitreomacular TractionGlaucoma

OCT imaging/HRT imaging

Universitaire Ziekenhuizen KU Leuven350 participants1 site · BelgiumCompletes Apr 2025

Compare CT.gov Full analysis →

Recruiting

Phase 1Geographic AtrophyAge-related Macular Degeneration

RO7669330Syfovre™Izervay™

Hoffmann-La Roche132 participants16 sites · United StatesCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

N/AGeographic AtrophyMacular Degeneration

Avacincaptad pegol (ACP)

Astellas Pharma Global Development, Inc.1,000 participants65 sites · United StatesCompletes Jan 2030

Compare CT.gov Full analysis →

Recruiting

Pharmacokinetics and Safety of Dexamethasone Eye Drops in Preterm Infants

Phase 1Retinopathy of Prematurity

Dexamethasone Ophthalmic

Region Skane15 participants2 sites · SwedenCompletes Jun 2025

Compare CT.gov Full analysis →

Recruiting

REtinal Detachment Outcomes Study

N/ARetinal Detachment

Pars plana vitrectomyPars plana vitrectomy with scleral buckleSulfur hexafluoride gas tamponade+1 more

CHU de Quebec-Universite Laval560 participants1 site · CanadaCompletes Jul 2027

Compare CT.gov Full analysis →

Recruiting

Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant

N/ADiabetic Macular EdemaVisual ImpairmentDiabetes Mellitus

Anti-VEGF treatmentDexamethasone implantTreatment with intravitreal anti-VEGF OR Dexamethasone implant

Vastra Gotaland Region150 participants2 sites · SwedenCompletes Dec 2028

Compare CT.gov Full analysis →

1–15 of 153